Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders by Eltahla, Auda A et al.
Cross-Genotypic Examination of Hepatitis C Virus Polymerase
Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders
Auda A. Eltahla,a Enoch Tay,b Mark W. Douglas,b Peter A. Whitea
School of Biotechnology and Biomolecular Sciences, Faculty of Science, University of New South Wales, Sydney, Australiaa; Storr Liver Unit, Westmead Millennium
Institute, University of Sydney at Westmead Hospital, Sydney, Australiab
Direct-acting antivirals (DAAs) targeting proteins encoded by the hepatitis C virus (HCV) genome have great potential for the
treatment of HCV infections. However, the efficacy of DAAs designed to target genotype 1 (G1) HCV against non-G1 viruses has
not been characterized fully. In this study, we investigated the inhibitory activities of nonnucleoside inhibitors (NNIs) against
the HCV RNA-dependent RNA polymerase (RdRp). We examined the ability of six NNIs to inhibit G1b, G2a, and G3a sub-
genomic replicons in cell culture, as well as in vitro transcription by G1b and G3a recombinant RdRps. Of the six G1 NNIs, only
the palm II binder nesbuvir demonstrated activity against G1, G2, and G3 HCV, in both replicon and recombinant enzymemod-
els. The thumb I binder JTK-109 also inhibited G1b and G3a replicons and recombinant enzymes but was 41-fold less active
against the G2a replicon. The four other NNIs, which included a palm I binder (setrobuvir), two thumb II binders (lomibuvir
and filibuvir), and a palm-hairpin binder (tegobuvir), all showed at least 40-fold decreases in potency against G2a and G3a rep-
licons and the G3a enzyme. This antiviral resistance was largely conferred by naturally occurring amino acid residues in the G2a
and G3a RdRps that are associated with G1 resistance. Lomibuvir and filibuvir (thumb II binders) inhibited primer-dependent
but not de novo activity of the G1b polymerase. Surprisingly, these compounds instead specifically enhanced the de novo activity
at concentrations of>100 nM. These findings highlight a potential differential mode of RdRp inhibition for HCVNNIs, depend-
ing on their prospective binding pockets, and also demonstrate a surprising enhancement of de novo activity for thumb RdRp
binders. These results also provide a better understanding of the antiviral coverage for these polymerase inhibitors, which will
likely be used in future combinational interferon-free therapies.
Nearly 3% of the world’s population is infected with hepatitis Cvirus (HCV), a leading cause of chronic liver disease and
hepatocellular carcinoma (1). A member of the Flaviviridae fam-
ily, HCV is an enveloped virus which has a positive-sense, single-
stranded RNA (ssRNA) genome of 9.6 kb. Upon infection, the
genome is translated into a single polyprotein that is then pro-
cessed into structural and nonstructural proteins. The genome
shows substantial heterogeneity, and therefore HCV has been
classified into six different genotypes (G1 to G6), which are ap-
proximately 35% divergent at the nucleotide level (2). Genotypes
are further classified into subtypes (1a, 1b, 1c, etc.), with about
20% intersubtype nucleotide divergence (2).
Until recently, treatment of HCV infections involved a combi-
nation of pegylated interferon and ribavirin (PEG-IFN/RBV), a
regimen that is lengthy and poorly tolerated and has various re-
sponse rates among the HCV genotypes. Among patients infected
with the most prevalent HCV genotype, G1, around 50% achieve
a sustained virological response (SVR) with PEG-IFN/RBV ther-
apy, compared to 80% of those infected with G2 or G3 viruses
(3). For more than a decade, extensive efforts have been devoted to
the development of direct-acting antivirals (DAAs), compounds
which specifically inhibit HCV replication by targeting viral non-
structural proteins. Three protease inhibitors have so far been
approved for treatment of HCV G1, in combination with PEG-
IFN/RBV, and have increased SVR rates by nearly 30% compared
to those with PEG-IFN/RBV therapy alone for that particular ge-
notype (4–7). The first HCV nucleoside inhibitor (NI), sofosbu-
vir, was also recently approved for HCV treatment in combination
with PEG-IFN/RBV, with SVR rates of around 90% in HCV pa-
tients, although the drug is less effective against G3a viruses in
IFN-free regimens (8–10). These four approved HCV DAAs rep-
resent the forerunners of a group of around 30 DAAs in phase 2 or
3 clinical trials (11).
The HCV RNA-dependent RNA polymerase (RdRp) has long
been a prime target for antiviral development because of its critical
role in viral replication and the absence of a mammalian homol-
ogous enzyme. The RdRp has a “right-hand” structure with finger
and thumb domains that encircle the active site, located in the
palm domain (12–14). Current DAAs targeting the HCV RdRp
are classified into two groups. Nucleoside inhibitors, such as so-
fosbuvir, are substrate analogues that cause termination during
synthesis of new RNA molecules. In contrast, the binding of non-
nucleoside inhibitors (NNIs) to the RdRp inhibits conformational
changes essential for polymerase activity (15). HCV NNIs have
been identified as encompassing a diverse range of chemical scaf-
folds (16). However, these have all been found to bind the RdRp at
one of five NNI sites (reviewed in reference 17). Two binding sites
lie within the thumb subdomain: thumb I (T1), to which com-
pounds such as benzimidazole and indole derivatives (e.g., de-
leobuvir, BMS-791325, and TMC647055) bind, and thumb II
(T2), which is the target site for thiophene-2-carboxylic acids (18),
such as VX-222 (lomibuvir) and GS-9669, as well as dihydropy-
ranones, such as PF-00868554 (filibuvir) (19). Two other NNI
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sites have been characterized within the palm domain, distinct
from but in close proximity to the RdRp active site. The palm I site
(P1) has been targeted by proline (20), benzodiazepine (21), and
benzothiadiazine (22) derivatives, such as RG7790 (setrobuvir),
ABT-333, and ABT-072, whereas compounds that bind to the
palm II site (P2) include benzofurans, such as HCV-796 (nesbu-
vir) (23). Imidazopyridines, including the NNI GS-9190 (tegobu-
vir), are another class of compounds which bind to the palm site of
the polymerase; however, unlike other palm binders, this binding
uniquely involves an interaction with the-hairpin which extends
from the thumb into the palm domain (site P-) (24, 25).
The lack of a cell culture model for HCV genotypes other than
G1 and G2 (26) has significantly hindered the development of
antivirals specifically targeting HCV genotypes G3 to G6. Studies
to determine the efficacy of HCV G1-developed NNIs on G3 to G6
viruses have therefore largely involved recombinant enzymes
made inEscherichia coli (27, 28) or the use of chimeric subgenomic
replicons containing the NS5B coding region on a G1b/G2a back-
bone (29–32). However, chimeric replicons are often prone to
replication fitness losses, and the contribution of the backbone
RNA/proteins to the differential antiviral effects is poorly charac-
terized (29). Recently, replicons of HCV G3a and G4a were de-
scribed (33–35), therefore allowing a closer examination of the
efficacies of HCV G1 DAAs against G2 to G6 viruses, which rep-
resent between 35% and 90% of all HCV infections in some coun-
tries (36–40).
The RdRp of HCV, like those of other members of the Flavi-
viridae family, can catalyze transcription through primed elonga-
tion as well as through a primer-independent (de novo) mecha-
nism (41–43). De novo polymerase activity is believed to be the
mechanism by which viral genome replication is initiated in vivo,
and it is critical for the preservation of the terminal ends of the
ssRNA genome during replication (42). The two modes of RdRp
activity are believed to correspond to different conformations of
the enzyme. A “closed” conformation, facilitated by the interac-
tions between the finger and thumb domains, allows the de novo
formation of a dinucleotide for replication initiation (44). The
more relaxed “open” conformation of the HCV RdRp is formed
by displacement of the -hairpin loop as well as a C-terminal
segment just upstream of the transmembrane domain, called the
linker (45, 46). This open conformational change allows room for
the nascent double-stranded RNA (dsRNA) and is thought to be
responsible for the primer-extension activity of the RdRp (45, 46).
Studies involving NNIs and recombinant RdRps have focused pri-
marily on the ability of the NNIs to inhibit the primer-dependent
activity of the HCV RdRp, and little is currently known on what
effect NNIs have on de novo RdRp activity. Yi et al. (47) recently
demonstrated that T2-binding HCV NNIs inhibited the primed
activity but had little effect on the de novo activity of the HCV G1b
RdRp. Conversely, compounds which bound to the P1 and P2
sites inhibited both modes of RdRp activity (47, 48). These com-
pounds, however, were examined using only a narrow range of
concentrations (0 to 200 nM), and the effects of NNI binding to
the T1 and P- sites remain to be examined (47). Furthermore, it
is unclear how the various NNIs affect both modes of activity, i.e.,
de novo and primed elongation, across RdRps of different HCV
genotypes.
In this study, RdRp inhibitors representing molecules that
bind to all known sites on HCV polymerase were screened for the
ability to inhibit G1b, G2a, and G3a replicons and G1b and G3a
recombinant enzymes. Furthermore, the inhibitory profiles of
HCV NNIs against de novo and primed RdRp activity were ana-
lyzed, revealing a novel mechanism of action for T2 and P-
binders.
MATERIALS AND METHODS
Compounds. All compounds were purchased from commercial vendors,
dissolved in 100% dimethyl sulfoxide (DMSO), and freshly diluted to the
desired concentration on the day of the experiment. These compounds
included 2=-C-methylcytidine (2CM) (Sigma-Aldrich, St. Louis, MO),
JTK-109 (Dalton Pharma Services, Toronto, Canada), tegobuvir (GS-
9190) and nesbuvir (HCV-796) (Haoyuan Chemexpress, Shanghai,
China), filibuvir (PF-00868554) and setrobuvir (ANA-598) (Acme Bio-
sciences, Palo Alto, CA), and lomibuvir (VX-222) (Selleckchem, Hous-
ton, TX). The structures of molecules examined in this study are shown in
Fig. 1.
Quantitative RdRp assays. Recombinant RdRps were expressed in E.
coli and purified by affinity chromatography as described previously (49,
50). Recombinant RdRps used in this study were those from HCV G1b
strain Con1 (GenBank accession number AJ238799) and G3a strain
VRL69b (accession number EF189901) (50). The de novo activity of
RdRps was measured by monitoring the formation of double-stranded
RNA from a single-stranded homopolymeric template, poly(C), by using
the fluorescent dye PicoGreen (Invitrogen, Carlsbad, CA) as described
previously (49). Alternatively, radioactive-nucleotide incorporation as-
says (1 Ci [3H]rGTP/reaction mix) were also used to measure enzyme
activity (50). Half-maximal inhibitory concentration (IC50) values were
calculated for each compound by nonlinear regression in GraphPad
Prism, version 6.02.
Gel-based RdRp assays. Polyacrylamide gel-based assays were used to
examine the two mechanisms of RdRp activity, i.e., primer extension and
primer-independent (de novo) activities, using the method described by
Yi et al. (47). The RNA template PE46 was designed to direct primer
extension activity through a stable hairpin at the 3= end, whereas the
template LE19p can direct only de novo RdRp activity due to the addition
of puromycin at the 3= end of the RNA (47). Reactions were performed
using either 1 M PE46 or 0.5 M LE19p. Each reaction mixture con-
tained 240 nM RdRp, 0.2 mM rGTP, 0.1 mM (each) rCTP, rATP, and
rUTP, 5 mM dithiothreitol (DTT), 2.5 mM MnCl2, and 20 mM Tris-HCl
in a 25-l final volume. Reaction mixtures were incubated for 5 h at 30°C
in the presence of test compounds or the compound vehicle DMSO (0.5%
[vol/vol]). PE46 products were run in 15% denaturing polyacrylamide
gels containing 7 M urea (Bio-Rad, Hercules, CA), whereas LE19p prod-
ucts were run in urea-free 15% polyacrylamide gels (Bio-Rad). Gels were
stained with SYBR green II (Invitrogen) and visualized on a Gel Doc
molecular imager (Bio-Rad). RNA band intensities were quantified by
densitometry using ImageJ (version 1.46r).
Cells, replicons, and plasmids. A bicistronic HCV G1b replicon con-
taining a luciferase reporter gene (51) was kindly provided by Ralf Bar-
tenschlager (University of Heidelberg, Germany). The bicistronic G3a
replicon S52/SG-Feo, containing a chimeric gene encoding firefly lucifer-
ase fused with neomycin phosphotransferase (33), was kindly provided by
Charlie Rice (The Rockefeller University, New York). The plasmid for a
tricistronic HCV G2a replicon (tri-JFH1) (52) was kindly provided by
John McLauchlan (The University of Glasgow, Scotland). For the G2a
replicon, RNA transcripts were generated and electroporated into Huh-7
cells for clonal selection. Cells were grown in the presence of 750g/ml of
Geneticin for 3 weeks, and surviving colonies were isolated and charac-
terized for replicon RNA levels and HCV NS5a expression as described
previously (53).
HCV replicon assays. The antiviral activity of HCV NNIs was exam-
ined using G1b, G2a, and G3a replicon-bearing cells and increasing con-
centrations of each test compound (0.01 nM to 100 M). The nucleoside
inhibitor 2CM was used as a positive control for replicon inhibition.
Huh-7 (G1b and G2a) or Huh-7.5 cells (G3a) bearing the HCV sub-
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genomic replicons were seeded into 96-well plates at a density of 5,000
cells/well in antibiotic-free Dulbecco’s modified Eagle’s medium
(DMEM). On the next day, compounds were freshly diluted in complete
medium, added to the cells, and incubated for 72 h. Untreated cells were
incubated with 0.5% DMSO, the compound vehicle. Replication of the
HCV replicons was determined by luciferase activity, measured using a
luciferase assay system kit (Promega, Madison, WI) following the manu-
facturer’s instructions. Luminescence was measured on a FLUOstar Op-
tima microplate reader (BMG Labtech, Ortenberg, Germany). Replica-
tion of HCV replicons in treated cells was compared to that in untreated
cells to calculate percent inhibition. Half-maximal effective concentration
(EC50) values were determined by nonlinear regression in GraphPad
Prism, version 6.02.
RESULTS
Inhibitory activity of NNIs against HCV replicons. In order to
examine the cross-genotype activity of HCV NNIs, replicons of
HCV G1b, G2a, and G3a were used. Compounds were selected
which bind to each of the five known NNI sites, and their ability to
inhibit HCV replicon replication was assessed at increasing con-
centrations (0.01 nM to 100 M). As a positive control, 2CM, an
NI known to be an HCV cross-genotypic inhibitor, was also used.
All three HCV replicons were susceptible to inhibition by 2CM.
Specifically, the EC50 for the G1b replicon was 767.1 nM; however,
5-fold (3.8 M) and 3-fold (2.2 M) increases in EC50 were ob-
served with the G2a and G3a replicons, respectively (Fig. 2; Table 1).
In contrast, the five NNIs demonstrated differential inhibitory
efficacies across replicons of genotypes 1b, 2a, and 3a. First, the P1
inhibitor setrobuvir demonstrated a significant loss of inhibitory
activity against HCV G2a and G3a replicons in comparison to the
EC50 of 8.1 nM for the G1b replicon. Only 44% 14.6% inhibi-
tion of G2a replicon replication was observed with the maximal
concentration of 100 M (12,000-fold increase in EC50). Simi-
larly, when examined using the G3a replicon, the EC50 was 26.1
M, or3,200-fold higher than that for the G1b replicon (Fig. 2;
Table 1). The P2 inhibitor nesbuvir had an EC50 of 16.6M when
examined using the G1b replicon, and it showed comparable ac-
tivities against all three genotypes, with only 3-fold and 2-fold
reductions in potency against G2a (EC50  43.3 M) and G3a
(EC50  39.9 M) replicons, respectively, compared to the G1b
replicon (Fig. 2; Table 1). Overall, these results show that the P2
binder nesbuvir is a better cross-genotype inhibitor than the NNI
setrobuvir, which binds to the P1 site.
Among the thumb binders, JTK-109, which binds to the T1
site, inhibited the replication of the G1b replicon with an EC50 of
257.1 nM, while a 6-fold increase in EC50 was observed for the G3a
replicon (EC50  1.5 M) and a 41-fold increase in EC50 was
observed for the G2a replicon (EC50 10.6M) (Fig. 2; Table 1).
Both T2 binders, lomibuvir and filibuvir, inhibited the G1b repli-
con, with EC50s of 5.9 nM and 79.2 nM, respectively. These two T2
inhibitors appeared to be specific G1b inhibitors, with a signifi-
cant loss of inhibitory activity observed with lomibuvir against the
G2a and G3a replicons (678-fold and 2,000-fold increases, re-
spectively, in the EC50), while filibuvir demonstrated 40-fold and
59-fold increases in the EC50 for the G2a and G3a replicons, re-
spectively (Table 1). Lastly, tegobuvir, a P- binder, inhibited the
replication of the G1b replicon with an EC50 of 3.2 nM, but its
inhibitory activity was significantly reduced against G2a (3,400-
fold) and G3a (822-fold) replicons compared to the G1b replicon
(Fig. 2; Table 1).
Inhibitory activity of HCV NNIs against recombinant
RdRps. The effects of HCV NNIs on the de novo activity of G1b
and G3a RdRps were analyzed using an RdRp fluorescence assay.
Inhibition of recombinant RdRp activity was measured by the
reduction of dsRNA produced from a poly(C) template, as deter-
mined by PicoGreen fluorescence, and compared to control reac-
tions (49). Consistent with replicon results, the P1 binder setro-
buvir inhibited the G1b RdRp with an IC50 of 157.5 nM and was
17-fold less potent when examined using the G3a RdRp (IC50 
2.6 M) (Fig. 3; Table 2). In contrast to setrobuvir, and also con-
sistent with the replicon results, the P2 RdRp inhibitor nesbuvir
demonstrated similar efficacies against both G1b and G3a RdRps,
with IC50s of 76.7 nM and 75.0 nM, respectively (Fig. 3; Table 2).
In a similar pattern, JTK-109 (T1 binder) showed comparable
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inhibitory activities against both G1b and G3a RdRps, with IC50s
of 35.4 nM (G3a) and 107.6 nM (G1b) (Table 2).
Surprisingly, when the T2 binders were examined using the
RdRp fluorescence assay, an increase in the de novo activity of the
HCV G1b RdRp was observed as measured by increased dsRNA
formation (Fig. 3). Upon the addition of both lomibuvir and fili-
buvir, which inhibited the G1 replicon, the G1b RdRp de novo
activity appeared to increase 50% at 100 nM and100% at 1 M
(Fig. 3). This effect was not observed for the G3a RdRp, i.e., the de
novo activity for the G3a enzyme was not induced by lomibuvir or
filibuvir (Fig. 3). In fact, lomibuvir inhibited the G3a de novo
RdRp activity, but only at higher concentrations (45.5%  6.6%
inhibition at 100 M), whereas filibuvir did not inhibit the G3a
RdRp at any of the examined concentrations (Fig. 3). Induction of
the de novo activity of the G1b RdRp was not limited to T2 binders,
as tegobuvir, which binds to the P- site, also specifically en-
hanced G1b RdRp activity, although this effect was not as potent
as that of lomibuvir or filibuvir, with a 75.5% 7.5% increase in
G1b RdRp activity at 100 M (Fig. 3). Tegobuvir had no observ-
able effect on the activity (enhancement or inhibition) of the G3a
RdRp (Fig. 3).
In order to eliminate the possibility that the enhancement of
G1b de novo RdRp activity by T2- and P--binding NNIs was an
artifact of the PicoGreen assay system, an alternative radioactive-
nucleotide incorporation assay was used, with lomibuvir as a rep-
resentative of the three de novo activity-enhancing NNIs. A
marked increase in the de novo activity of the G1b enzyme by
lomibuvir was again seen with the radioactive assay; de novo activ-
ity increased by 39.1% 10.6% at 100 nM and by 115% 29.7%
at 10 M. Lomibuvir did not enhance the de novo activity of the
G3a RdRp (data not shown). In the radioactive assay, lomibuvir
also inhibited both G1b and G3a RdRps at very high concentra-
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FIG 2 Inhibitory activities of HCV NNIs against subgenomic replicons. The activities of HCV NNIs were examined using subgenomic replicons of HCV G1b
(blue bars), G2a (red bars), and G3a (green bars), which all contained luciferase reporter genes. Cells harboring HCV replicons were treated with the compounds,
and luciferase activity was measured 72 h later. Results are shown as percentages of the mock (0.5% [vol/vol] DMSO) treatment level. Data are the averages and
standard deviations of results from triplicate experiments.
TABLE 1 Cross-genotype activities of HCV inhibitors against subgenomic replicons
Compound
Binding
site
G1b replicon G2a replicon G3a replicon
EC50 (nM) 95% CI
a EC50 (nM) 95% CI
a Fold changeb EC50 (nM) 95% CI
a Fold changeb
2CM NI 767.1 520.5–1,130 3,765 1,548–9,156 5 2,249 1,437–3,517 3
Setrobuvir P1 8.1 6.1–10.6 100,000 12,000 26,060 17,690–38,390 3,217
Nesbuvir P2 16.6 10.9–25.4 43.3 27.3–68.8 3 39.9 27.4–58.1 2
JTK-109 T1 257.1 153.6–430.2 10,620 6,434–17,520 41 1,508 944–2,409 6
Lomibuvir T2 5.9 4.4–7.9 3,998 2,406–6,643 678 12,030 8,744–16,540 2,039
Filibuvir T2 79.2 55.8–112.6 3,176 1,904–5,296 40 4,698 3,448–6,401 59
Tegobuvir P- 3.2 2.3–4.3 10,960 3,207–37,440 3,425 2,629 1,845–3,746 822
a CI, confidence interval.
b Fold change in EC50 compared to that obtained using the G1b replicon.
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tions, and it was more potent against the G3a RdRp (81% 1.5%
inhibition) than against the G1b RdRp (41% 3.3% inhibition)
at 100 M (data not shown).
Gel-based examination of RdRp inhibition. The mechanism
of G1b RdRp inhibition by the different NNIs was further ana-
lyzed using two gel-based assays described by Yi et al. (47). Only
the G1b RdRp was used for this analysis, as it is the target enzyme
for all six NNIs used in this study. The PE46 template is designed
to form a hairpin to initiate primed transcription (47), while the
LE19p template has a puromycin modification of the 3= terminus,
allowing only de novo dsRNA synthesis (47). NNIs that bind to the
palm and thumb sites (T1, T2, P1, and P2) inhibited the primer-
dependent activity of the G1b RdRp, as assessed using the PE46
template (Fig. 4A). These inhibitors exerted inhibitory activity at
concentrations between 10 nM and 100 nM, with 82% inhibi-
tion at 1M, with the exception of JTK-109, which required con-
centrations of 1 M and 10 M for 45% and 84% inhibitions of
G1b RdRp activity, respectively (Fig. 4A).
Gel-based analysis of the de novo G1b RdRp activity was per-
formed to confirm observations of enhanced RdRp activity by T2-
and P--binding NNIs in the quantitative fluorescence and radio-
active in vitro assays (Fig. 3). In the gel-based assay, inhibitors
which bound to the P1, P2, and T1 sites abolished the de novo
activity of the HCV G1b RdRp when examined at concentrations
of 100 nM (Fig. 4B). In contrast, an increase in de novo RdRp
activity was again observed with the T2 inhibitors lomibuvir and
filibuvir. The addition of lomibuvir resulted in an 80% increase in
the de novo activity at 100 nM and a 180% increase at 1 M (Fig.
4B), as quantified by densitometry (data not shown), but at a
higher concentration (100M), a modest (4.5%) reduction in the
activity was observed (Fig. 4B). In the gel-based assays, filibuvir
also enhanced de novo transcription of the G1b RdRp, with a 27%
increase at 100 nM, a 76% increase at 1M, a 144% increase at 10
M, and a 240% increase at 100 M, as quantified by densitom-
etry (Fig. 4B). Overall, these results are consistent with the pattern
observed using the fluorescence and radioactive RdRp assays,
where T2 binders enhanced the de novo activity but inhibited
primed elongation of the HCV G1b RdRp. The P- binder
tegobuvir had no observable effect on G1b RdRp activity when
examined using either the primed or de novo gel-based assays
(data not shown).
Analysis of resistancemutations inHCVRdRp sequences. In
order to gain insights into the differential efficacy of HCV inhib-
itors, the amino acid sequences for the G1, G2, and G3 RdRps were
analyzed for known substitutions conferring resistance to all com-
pounds tested in this study (reviewed in reference 54). A summary
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FIG3 Effects of HCV NNIs on de novo activity of recombinant G1b and G3a RdRps. The inhibitory activities of HCV NNIs were examined using G1b (blue bars)
and G3a (green bars) recombinant RdRps. Assays were performed using a homopolymeric poly(C) RNA template, and RdRp activity was measured via the
quantitation of dsRNA formation using the fluorescent dye PicoGreen. RdRp activity is shown as a percentage of control reactions incubated with the compound
vehicle DMSO (0.5% [vol/vol]). Data are the averages and standard deviations of results from triplicate experiments.
TABLE 2 Inhibitory activities of HCV NNIs against recombinant RdRps
Compound Site
G1b RdRp G3a RdRp
IC50 (nM) 95% CI
a IC50 (nM) 95% CI
a
Fold
changeb
Setrobuvir P1 157.5 82.8–299.5 2,605.0 1,392–4,873 17
Nesbuvir P2 76.7 21.6–271.9 75.0 57.6–97.7 1
JTK-109 T1 107.6 45.6–253.8 35.4 15.0–83.6 0.3
Lomibuvir T2 Enhanced 100,000
Filibuvir T2 Enhanced 100,000
Tegobuvir P- Enhanced 100,000
a CI, confidence interval.
b Fold change in IC50 compared to that obtained with the G1b RdRp.
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of amino acid substitutions associated with G1b resistance to the
NNIs in this study is shown in Fig. 5. Residues are also shown for
the RdRps from the G2a (JFH-1) and G3a (S52) replicon strains
and for the G3a strain VRL69b. HCV G3a VRL69b was used for
recombinant enzyme experiments in this study and differed from
the S52 G3a RdRp by only 6 amino acids, none of which are known
to confer resistance to HCV RdRp inhibitors (Fig. 5).
Examination of HCV G2a and G3a RdRp sequences revealed
multiple naturally occurring resistance residues in both G2a and
G3a RdRps, which likely confer resistance to HCV NNIs that bind
to the P1, T2, and P- sites but not to NNIs which bind to P2 or
T1. Specifically, residues G556 and F445, implicated in G1 RdRp
resistance to setrobuvir (P1) (55, 56) and tegobuvir (P-) (25),
respectively, were found in both G2a and G3a RdRp sequences
(Fig. 5). Both G2a and G3a RdRps contained residues I419 and
L482 (27, 29) (Fig. 5), which are associated with resistance to the
T2 binders lomibuvir and filibuvir (47, 57, 58). Furthermore, the
amino acid residue A494, also associated with T2 NNI resistance
in G1b, was present in the G2a RdRp sequence but not in the G3a
RdRp sequence (Fig. 5). The amino acid substitution V494A has
been selected in vivo after treatment of G1 HCV-infected patients
with lomibuvir (72), and also by us in vitro, using the G1b replicon
(unpublished data). In contrast, none of the substitutions previ-
ously known to confer resistance to JTK-109 (T1) and nesbuvir
(P2) were present in G2a or G3a RdRp (29) (Fig. 5).
DISCUSSION
The standard of care for treatment of HCV infection is currently
undergoing significant changes, moving from traditional interfer-
on-based regimens to shorter, interferon-free combination DAA
regimens. Several dozen DAAs are in different stages of clinical
trials (11), and four have so far been approved for use in combi-
nation with PEG-IFN/RBV. With all-oral, interferon-free combi-
nation therapies now on the horizon, a better understanding of
the cross-genotypic specificities and modes of action for the dif-
ferent G1 NNIs is warranted, particularly as replicons are now
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FIG 4 Effects of HCV G1 NNIs on primed and de novo RdRp activities. The
effects of HCV NNIs on primed and de novo activities of the HCV G1b RdRp
were analyzed using gel-based assays. Reaction mixtures were run in the ab-
sence of compound (negative control), in the absence of RdRp (positive con-
trol), and in the presence of increasing compound concentrations (0.01 nM to
100 M). (A) Primer-dependent activity was examined using the PE46 RNA
template, and reaction products were analyzed in a 15% denaturing gel. (B)
Primer-independent or de novo RdRp activity was analyzed using LE19p, and
products were run in a 15% nondenaturing gel. The RNA templates PE46 and
LE19p are the bottom bands in both panels, and the RdRp products are the top
bands. P1, P2, and T1 binders inhibited both modes of G1b RdRp activity at
concentrations of100 nM. At the same concentrations, however, T2 binders
inhibited primed transcription (A) while unexpectedly enhancing de novo ac-
tivity, by 80% (lomibuvir) and 27% (filibuvir) (B). The two T2 binders also
enhanced G1b de novo RdRp activity at 1 M, by 180% (lomibuvir) and 76%
(filibuvir), as quantified by densitometry.
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available for other HCV genotypes. In this study, we examined six
representative NNIs, which between them bind to all five RdRp
binding pockets, for the ability to inhibit G1, G2, and G3 HCV
replicons. Furthermore, the ability of the NNIs to inhibit both
modes of transcription, i.e., de novo and primed elongation, was
also assessed. Of the NNIs selected for this study, lomibuvir, se-
trobuvir, and tegobuvir are currently in phase II clinical trials,
whereas clinical development has been halted for JTK-109, nesbu-
vir, and, more recently, filibuvir (59).
Examination of the cross-genotypic efficacy of the NNI setro-
buvir (P1 binder) revealed that it had little effect on the replication
of the G2a (EC50 100 M) and G3a (EC50 26 M) replicons
compared to that of the G1b replicon (EC50 8.1 nM) (Table 1).
Similarly, recombinant G3a RdRp was far less susceptible to inhi-
bition by setrobuvir (IC50 2.6M) than G1b RdRp was (IC50
157.5 nM) (Table 2). The loss of activity of benzothiadiazines,
such as setrobuvir, against G2a and G3a viruses is consistent with
previous reports on chimeric replicons (29, 30, 32) and recombi-
nant G2a and G3a RdRps (27, 28). Resistance to benzothiadiazines
in G2a and G3a viruses appears to be due to the glycine residue at
position 556 (55, 56) of the RdRp, an amino acid substitution
which was detected in benzothiadiazine-resistant G1 replicons
(60) and in G1 HCV-infected patients after treatment (61). Sur-
prisingly, mutating G556 in the G3a RdRp to a serine, the residue
naturally occurring in the G1b enzyme, did not confer suscepti-
bility to benzothiadiazines, at least in recombinant RdRp studies
(27). Thus, the precise mechanism of G3a resistance to this class of
molecules remains to be resolved.
Of the six NNIs examined, only nesbuvir (site P2) demon-
strated cross-genotypic inhibitory activity against G1b, G2a, and
G3a replicons, with EC50s between 16.6 nM and 43.3 nM (Table
1). Nesbuvir also inhibited the de novo activity of the G3a RdRp,
with an IC50 of 75 nM, compared to 76.7 nM for the G1b RdRp
(Table 2). These findings are consistent with previous studies us-
ing HCV replicons and RdRps, where nesbuvir demonstrated
equivalent potencies against all HCV genotypes (28–30, 32, 62),
and correspond with the absence of naturally occurring substitu-
tions in the P2 binding region of G2a and G3a RdRps.
In addition to inhibiting the G1b replicon (EC50 257.1 nM)
and G1b RdRp (EC50  107.6 nM), the benzimidazole JTK-109
(site T1) demonstrated similar inhibitory activities against the
G3a replicon (EC50  1.5 M) and enzyme (IC50  35.4 nM).
However, JTK-109 was 41-fold less potent against the G2a repli-
con (Fig. 2; Table 1). The reasons for the reduced efficacy of T1
binders, such as JTK-109, against G2a viruses are not fully under-
stood (29). For instance, although substitutions at the P495 resi-
due are known to confer resistance to JTK-109 in both G1b repli-
con and recombinant enzyme models (63), these residues are not
observed in the G2a RdRp (Fig. 5). However, a naturally occurring
alanine at position 494 in the G2a RdRp, which is not present in
the susceptible G3a RdRp, may explain the reduced inhibitory
activity of T1 binders against the G2a replicon (Fig. 5). Indeed, the
V494A substitution has been associated with resistance of recom-
binant G1b RdRp to other thumb I binders, such as indole-N-
acetamides (64), and further work is needed to confirm if this
substitution confers JTK-109 resistance.
Resistance to the T2 inhibitors lomibuvir and filibuvir has been
attributed to L419I and I482L substitutions in the HCV RdRp (47,
57, 58), both of which are present in G2a and G3a viruses (27, 29).
This is consistent with our finding of a lack of activity for these
drugs against G2a and G3a replicons (Fig. 5), against which T2
binders were much less potent than the case against the G1b rep-
licon (Table 1). Tegobuvir (P- binder) was less potent against the
G2a (3,400-fold) and G3a (822-fold) replicons than against the
G1b replicon (Table 1). Resistance to tegobuvir in G2a and G3a
replicons is likely due to the C445F substitution (Fig. 5), which lies
in the -hairpin and has been shown to confer resistance to this
class of compounds in replicon studies (25). It is worth noting that
the reduced potencies of lomibuvir, filibuvir, and tegobuvir
against HCV G3a observed in this study are higher than those
recently reported for a different G3a replicon based on the same
HCV G3a strain, S52 (63-fold, 13-fold, and 22-fold, respectively)
(62), but more consistent with levels reported previously using
chimeric HCV replicons (29, 30, 32).
To our surprise, de novo but not primed RdRp activity of the
recombinant G1b RdRp was enhanced approximately 2-fold by a
1M concentration of the T2 binders lomibuvir and filibuvir and,
to a lesser degree, by the P- binder tegobuvir (Fig. 3 and 4). The
increased RdRp activity was detected using de novo RdRp assays
with both fluorescent and radioactive outputs and was further
confirmed by gel-based assays (Fig. 4), indicating that it was a true
effect and not an artifact of the assay used. Furthermore, no in-
crease in de novo activity was detected when these compounds
were examined using the G3a RdRp. When tegobuvir was exam-
ined using the gel-based RdRp assay, no effect on G1b RdRp ac-
tivity was detected, in contrast to the enhancement of G1b RdRp
activity seen using the RdRp fluorescence assay. This may reflect a
reduced assay sensitivity which meant that the lower level of RdRp
enhancement seen with tegobuvir than with lomibuvir and filibu-
vir (Fig. 3) could not be detected in the gel-based assay.
Most studies to date that have analyzed NNI RdRp inhibition
have used primer-dependent assays, so it is likely that the en-
hancement of de novo RdRp activity has gone unnoticed. In fact,
both thiophene-2-carboxylic acids (18) and dihydropyranones
(19, 65), the scaffolds from which lomibuvir and filibuvir, respec-
tively, were developed, were identified from high-throughput
screening studies using primed RdRp assays, and further evalua-
tion was achieved using the replicon model. In a recent study, Yi et
al. reported no observable effect on de novo activity of the G1b
RdRp by lomibuvir or filibuvir (47). However, lomibuvir and fili-
buvir were examined over a relatively narrow range of concentra-
tions (50 to 200 nM), and indeed, a small increase in RdRp activity
can be observed in Fig. 3 from that paper for lomibuvir and fili-
buvir at a concentration of 200 nM (47). In contrast to lomibuvir
and filibuvir, tegobuvir was identified using HCV replicon and
infectious (JFH-1) cell culture systems (24). Interestingly, in an-
other recent study, tegobuvir was shown to increase the G1b
primed RdRp activity by 50% at a concentration of 3.7 M but
resulted in a 40% inhibition at 100 M, an observation that the
authors were unable to explain (66). Although the RdRp assay
used in the latter study uses a self-primed RNA template, no mea-
sures were taken to block the de novo RdRp activity; therefore,
both modes of activity may be in operation in that assay system.
The effect was not observed with the T2 binders lomibuvir and
filibuvir in the same study (66). In summary, the enhancement of
the HCV RdRp activity by T2 and P-NNIs reported in this study
can be observed in two previous reports (47, 66); however, the
effect has so far gone unnoticed or unexplained.
The mechanism of action for tegobuvir and T2 inhibitors is
poorly understood. Tegobuvir requires intracellular activation to
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form a covalent inhibitor of the HCV RdRp (67) and is not
thought to interact with the enzyme before activation (66), al-
though, interestingly, no activation was needed to enhance de
novo RNA synthesis in the present study. In contrast, recent evi-
dence suggests that filibuvir and lomibuvir reduce RdRp binding
to RNA but do not block the interaction completely (66). Struc-
tural analysis of the RdRp in complex with thiophene-2-carboxy-
lic acids indicated that these molecules bind to the closed confor-
mation of the enzyme (68) and induce conformational changes
that may interfere with enzymatic activity (68, 69). Although the
authors of that study suggested that this resulted in an initiation-
incompetent enzyme, our results indicate that filibuvir and lo-
mibuvir in fact increase the initiation (de novo) but inhibit the
elongation activity of the G1b RdRp. Recently, recombinant HCV
RdRp was proposed to exist as a mixture of conformations which
are in dynamic equilibrium, with stabilization of one conforma-
tion occurring at the expense of the other in solution (45). Given
that formation of the first few phosphodiester bonds and the tran-
sition to elongation are two known rate-limiting steps of the HCV
RdRp reaction (44, 70, 71), it is likely that T2 and P- enhance the
initiation efficiency (de novo) of the HCV RdRp by stabilizing the
RdRp conformations required for these rate-limiting steps. How-
ever, further studies are needed to validate such effects and to
detail the mechanism of action for the thumb-interacting subset
of HCV NNIs.
In summary, we have analyzed the inhibitory activities of six
representative HCV inhibitors that bind to the five NNI sites
across three genotypes: G1b, G2a, and G3a. Our data indicate that
only the P2 inhibitor nesbuvir is cross-genotypic, as naturally oc-
curring amino acid residues in non-G1 RdRps largely confer re-
sistance against other NNIs. We also report a previously unchar-
acterized enhancement of de novo RdRp activity by the T2 binders
lomibuvir and filibuvir, as well as the imidazopyridine tegobuvir
(P-), which improves our understanding of the mechanisms by
which these compounds exert antiviral activity against HCV.
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